NCT02339701 is a NA clinical trial of IMRT in Prostate Cancer, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT02339701?

NCT02339701 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT02339701?

Interventions in NCT02339701: IMRT, SBRT.

What condition does NCT02339701 study?

NCT02339701 studies Prostate Cancer.

Is NCT02339701 still recruiting?

NCT02339701 is currently active, enrolled. Last updated 17 November 2025.

Last reviewed 2025-11-17 · How we verify

NCT02339701

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer

Active, enrolled NA Last updated 17 November 2025

What this trial tests

NA trial testing IMRT in Prostate Cancer in 68 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 January 2015

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	health services research
Enrollment	68
Start date	7 January 2015
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	1 location across Hong Kong

Drugs / interventions tested

IMRT
SBRT — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary goal of this phase II study is to compare the change of EPIC HRQOL scores (1-year minus baseline) between SBRT and IMRT.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The relevance of ototoxicity induced by radiotherapy.
Huang Y, Zhou H, An F, Zhao A, et al · · 2023 · cited 8× · PMID 37270526 · DOI 10.1186/s13014-023-02268-7
Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.
Poon DMC, Lam D, Wong KCW, Chu CM, et al · · 2021 · cited 6× · PMID 35049677 · DOI 10.3390/curroncol29010003

Verify or expand the search:

Other trials of IMRT

Trials testing the same drug.

NCT06764680 — Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanc · Phase 2 · recruiting
NCT06323239 — SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT06364826 — Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma · Phase 2 · not yet recruiting
NCT06080503 — Phase II Randomized Study of Hypofractionated Versus Conventional Radiotherapy · NA · recruiting
NCT06314334 — Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma · Phase 2 · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02339701 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 17 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02339701.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing